New hope: Alzheimer's trial targets tau tangles to slow memory loss
Disease control
Recruiting now
This study tests whether drugs that target tau protein, alone or with donanemab, can reduce tau buildup and slow memory decline in people aged 50-80 with early Alzheimer's. Participants will receive treatment for 30 months and undergo brain scans and cognitive tests. The goal is …
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC